Market Overview

Coherus BioSciences Shares Fall Following Q2 Sales Guidance


Coherus BioSciences (NASDAQ: CHRS) announced that UDENYCA preliminary unaudited net sales for the second quarter expected in the range of $79 million-$84 million.

Coherus BioSciences shares were trading lower by 13% at $19.77 on Monday morning. The stock has a 52-week high of $23.43 and a 52-week low of $8.32.

Related Links:

Fast Track Designation By FDA Granted For Prevail's Parkinson's Treatment

Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream

Posted-In: News Guidance


Related Articles (CHRS)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Morning Market Update: Markets Open Lower; Deutsche Bank To Cut 18K Jobs

UnitedHealthcare To Cover Inspire Medical's Sleep Apnea Treatment